PMID- 28913565
OWN - NLM
STAT- MEDLINE
DCOM- 20180416
LR  - 20231213
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 23
IP  - 1
DP  - 2018 Feb
TI  - A retrospective analysis of ramucirumab monotherapy in previously treated 
      Japanese patients with advanced or metastatic gastric adenocarcinoma.
PG  - 92-97
LID - 10.1007/s10147-017-1192-0 [doi]
AB  - BACKGROUND: The REGARD trial demonstrated that ramucirumab monotherapy improved 
      both overall survival (OS) and progression-free survival (PFS) compared with best 
      supportive care plus placebo as second-line treatment for patients with advanced 
      gastric cancer. However, the efficacy and safety of ramucirumab monotherapy for 
      previously treated Japanese patients with advanced gastric cancer remains 
      unknown. METHODS: Previously treated Japanese patients with advanced gastric 
      cancer who received ramucirumab monotherapy between June 2015 and March 2016 at 
      the Cancer Institute Hospital were enrolled in the study. OS, PFS, best overall 
      response, and safety profiles were retrospectively evaluated. RESULTS: Nineteen 
      patients were enrolled in this study. Ramucirumab monotherapy was generally 
      administered as third-line therapy. After a median follow-up period of 
      7.4 months, the median PFS was 2.1 months (95% CI 1.0-3.5), and median OS was 
      12.9 months (95% CI 2.3, not reached). In 13 patients who had measurable lesions 
      on radiologic examination, partial response was observed in one patient (7.7%) 
      and stable disease was observed in five patients (38.5%). A total of 12 patients 
      (63.2%) had adverse events (AEs). Common AEs included hypertension (8 patients, 
      42.1%), fatigue (6 patients, 31.6%), and bleeding (5 patients, 26.3%). Grade 3 
      AEs included gastrointestinal bleeding and aspiration pneumonia (1 patient each, 
      5.3%). CONCLUSIONS: Our data suggest that ramucirumab monotherapy in Japanese 
      patients with previously treated advanced gastric cancer has comparable efficacy 
      and safety profiles as reported in the REGARD trial.
FAU - Murahashi, Satoshi
AU  - Murahashi S
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Takahari, Daisuke
AU  - Takahari D
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. 
      daisuke.takahari@jfcr.or.jp.
FAU - Wakatsuki, Takeru
AU  - Wakatsuki T
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Fukuda, Naoki
AU  - Fukuda N
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Ichimura, Takashi
AU  - Ichimura T
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Ogura, Mariko
AU  - Ogura M
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Ozaka, Masato
AU  - Ozaka M
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Shinozaki, Eiji
AU  - Shinozaki E
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Nakayama, Izuma
AU  - Nakayama I
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Matsushima, Tomohiro
AU  - Matsushima T
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Osumi, Hiroki
AU  - Osumi H
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Chin, Keisho
AU  - Chin K
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
FAU - Yamaguchi, Kensei
AU  - Yamaguchi K
AD  - Department of Gastroenterology, The Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20170914
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/mortality/pathology
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Asian People
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Stomach Neoplasms/*drug therapy/mortality/pathology
MH  - Treatment Outcome
MH  - Ramucirumab
OTO - NOTNLM
OT  - Gastric Cancer
OT  - Japanese
OT  - Monotherapy
OT  - Ramucirumab
EDAT- 2017/09/16 06:00
MHDA- 2018/04/17 06:00
CRDT- 2017/09/16 06:00
PHST- 2017/05/17 00:00 [received]
PHST- 2017/08/31 00:00 [accepted]
PHST- 2017/09/16 06:00 [pubmed]
PHST- 2018/04/17 06:00 [medline]
PHST- 2017/09/16 06:00 [entrez]
AID - 10.1007/s10147-017-1192-0 [pii]
AID - 10.1007/s10147-017-1192-0 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2018 Feb;23(1):92-97. doi: 10.1007/s10147-017-1192-0. Epub 2017 
      Sep 14.